Top 10 Blue Chip Stocks To Invest In 2019

Shutterstock

Dont take any dividends for granted today. Business disruption is accelerating as entire industries are being eaten alive.

Uber and Lyft? Killed cabs.

Amazon (AMZN)? Its crushing retail, and starving their REIT landlords right before our very eyes.

And soon, they might team up to offer more same day deliveries and make more rivals obsolete!

These types of disturbances have added a new layer to contrarian investing. Before, it was as simple as buying stocks when they were out-of-favor and holding them until they became back in vogue. The Dogs of the Dow strategy, for example, usually beat the market by banking the highest blue chip dividend yields a sign that the tide was ready to turn back in the dogs favor.

Top 10 Blue Chip Stocks To Invest In 2019: Exactech Inc.(EXAC)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11
  • [By Lisa Levin]

    Exactech, Inc. (NASDAQ: EXAC) shares were also up, gaining 31 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.

Top 10 Blue Chip Stocks To Invest In 2019: NEW GOLD INC.(NGD)

Advisors’ Opinion:

  • [By Paul Ausick]

    New Gold Inc. (NYSEAMERICAN: NGD) dropped about 2.9% Monday to post a new 52-week low of $2.35. Shares closed at $2.42 on Friday and the stock’s 52-week high is $4.25. Volume was about 10% below the daily average of around 5.8 million shares. The gold mining company had no news.

  • [By Dan Caplinger]

    The stock market lost ground on Monday, sending major market benchmarks lower by more than half a percentage point. The Dow lost its grip on the 20,000 mark in the wake of concerns about economic growth and new U.S. immigration policy, and some believe that the broader geopolitical climate could have a negative impact on global commerce that in turn could start affecting multinational corporations’ business prospects. In addition, bad news from some individual companies weighed on the markets, and Transocean (NYSE:RIG), Rite Aid (NYSE:RAD), and New Gold (NYSEMKT:NGD) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

  • [By Paul Ausick]

    New Gold Inc. (NYSEAMERICAN: NGD) dropped about 3.8% Thursday to post a new 52-week low of $2.28. Shares closed at $2.37 on Wednesday and the stock’s 52-week high is $4.25. Volume was about 15% below the daily average of around 5.9 million shares. The company had no specific news.

Top 10 Blue Chip Stocks To Invest In 2019: Galapagos NV(GLPG)

Advisors’ Opinion:

  • [By David Zeiler]

    Bill Patalon’s initial stock pick was Galapagos NV (Nasdaq ADR: GLPG), a Belgian biotech company.

    Patalon was attracted to Galapagos’ strategy to target “orphan diseases,” afflictions that strike rarely and so often go ignored by the Big Pharma companies. He also liked that Galapagos had more than 50 drug discovery programs underway, and that it already had licensing agreements with several bigger players in the industry.

  • [By Stephen Mack]

    Our investing experts have made some tremendous picks over the last several years, outperforming the S&P 500 by 100%, 200%, or even as much as 700% in the case of Money Morning Executive Editor Bill Patalon’s 2012 pick of Galapagos NV (Nasdaq: GLPG).

  • [By Stephen Mack]

    Galapagos NV (Nasdaq: GLPG) is our big winner so far, gaining 578.8% since Money Morning Executive Editor Bill Patalon shared his recommendation with Money Morning readers in April 2012. The S&P 500 has gained 75.4% in the same time. Bill has renewed his recommendation for the Belgian biotech several times over the years, saying in 2016 that it has “an established history of piling on gains.” With an average gain of 110% a year, it’s hard to argue with that.

Top 10 Blue Chip Stocks To Invest In 2019: lululemon athletica inc.(LULU)

Advisors’ Opinion:

  • [By Chris Lange]

    Lululemon Athletica Inc. (NASDAQ: LULU) will report its most recent quarterly results on Wednesday as well. The consensus estimates are EPS of $0.52 and $609.71 million in revenue. Shares traded at $67.22 on Friday, in a 52-week range of $47.26 to $72.70. The consensus price target is $65.50.

  • [By Chris Lange]

    Lululemon Athletica Inc. (NASDAQ: LULU) is set to release its most recent quarterly results on Tuesday. The consensus forecast calls for $1.27 in EPS and $911.42 million in revenue. Shares traded on Fridays close at $79.51. The consensus price target is $84.33, and the 52-week range is $47.26 to $83.98.

  • [By Lisa Levin]

    Shares of Lululemon Athletica inc. (NASDAQ: LULU) got a boost, shooting up 15 percent to $68.99 after the company reported stronger-than-expected earnings for its third quarter and announced a $100 million stock buyback plan.

  • [By Peter Graham]

    Athletic apparel stock Lululemon Athletica inc (NASDAQ: LULU) reported Q2 2017 earnings after the Thursday market close with results toppingexpectations as online sales surged 30% after an effort to beef up the eCommerce strategy plus the Company raised its outlook. Net revenuegrew 13% to$581.1 millionas total comparable sales increased 7% and comparable store sales increased 2%, or increased by 2% on a constant dollar basis. Direct to consumer net revenue increased 29%, or increased 30% on a constant dollar basis. During the quarter the Company held an online warehouse sale. Excluding the impact of this sale, direct to consumer net revenue increased 15%, or increased 16% on a constant dollar basis. Net income was $48.711 million versus net income of $53.625 million. The Company ended the second quarter of fiscal 2017 with $721.2 million in cash and cash equivalents compared to $535.3 million at the end of the second quarter of fiscal 2016. The CEO commented:

  • [By Paul Ausick]

    Lululemon Athletica Inc. (NASDAQ: LULU) reported fiscal second-quarter 2017 results after markets closed Thursday afternoon. The yoga gear maker reported adjusted diluted earnings per share (EPS) of $0.39 on revenues of $581.1 million, compared with EPS of $0.38 on revenues of $514.5 million in the same period a year ago. The consensus estimates called for EPS of $0.35 on revenues of $567.6 million.

  • [By Peter Graham]

    Athletic apparel stock Lululemon Athletica inc (NASDAQ: LULU)reported earnings for the first quarter ended April30, 2017along witha plan to restructure its ivivva operations. Net revenuerose 5% to$520.3 millionas total comparable sales decreased 1% whiledirect to consumer net revenue was flat. Net income was $31.246 million versus $45.336 million. In addition, the earnings report stated:

Top 10 Blue Chip Stocks To Invest In 2019: Aimmune Therapeutics, Inc.(AIMT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Aimmune Therapeutics Inc (NASDAQ: AIMT) got a boost, shooting up 35 percent to $34.73 in response to failed DBVT peanut allergy trial.

    Exactech, Inc. (NASDAQ: EXAC) shares were also up, gaining 31 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.

  • [By Jim Robertson]

    Small cap clinical-stage biopharmaceutical stock Aimmune Therapeutics (NASDAQ: AIMT) is aclinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The Companys Characterized Oral Desensitization ImmunoTherapy (CODIT) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune Therapeutics first investigational biologic product using CODIT⒙is AR101 for the treatment of peanut allergy.AR101 has received the FDAs Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials where enrollment was announced last month.

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.20, with a consensus price target of $57.11 and a 52-week range of $15.97 to $40.65.

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11

Top 10 Blue Chip Stocks To Invest In 2019: Mallinckrodt plc(MNK)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Mallinckrodt (MNK) tumbled to the bottom of the S&P 500 today after its earnings topped the Street consensus but offered commentary that spooked investors.

    Agence France-Presse/Getty Images

    Shares of Mallinckrodt dropped 9.1% to $52.42, while the S&P 500 rose 0.1%.

    Barclays analyst Douglas Tsao and Morgan Williams callMallinckrodt’s plunge “outsized.” They explain why:

    In our view the sell-off afterMallinckrodt reported CY3Q16 earnings is outsized considering much of the disclosure on the call was largely expected, including specialty generics weakness and the 2017 outlook, which seemed relatively mild. While outsized Acthar contribution to EBITDA may be accounting for some of the sell-off, wed argue that there is benefit to the brand outperforming, especially considering the need to offset Therakos production issues in CY4Q16 and CY1Q17 as well as specialty generics weakness. We recognize some lingering headline risk associated with media reports criticizing the cost of Acthar to Medicare, after CMS released its prescription drug spending dashboard.

    Mallinckrodt’s market capitalization fell to $5.7 billion today from $6.2 billion yesterday. It reported net income of $306 million on revenue of $3.3 billion in 2015.

    This marks the third time in less than two weeks that Mallinckrodt was the S&P 500′s biggest loser.

  • [By Ben Levisohn]

    Mallinckrodt (MNK) tumbled to the bottom of the S&P 500 today as weakness that began last month even before its fourth-quarter earnings continued into year end.

    Agence France-Presse/Getty Images

    Mallinckrodtdropped 2.7% to $51.77 today, while the S&P 500 rose 0.2% to 2,268.88.

    Mallinckrodt was the biggest loser in the S&P 500 for two consecutive days in mid-November, and again after reporting its earnings.

    Mallinckrodt’s market capitalization fell to $5.5 billion today from $5.6 billion yesterday. It reported net income of $489 million on sales of $3.38 billion in fiscal 2016.

    Mallinckrodt has dropped 31% so far this year.

  • [By Johanna Bennett]

    Sell-side analysts continue to defend drug maker Mallinckrodts (MNK) shares on the heel of Citron Researchs report on the company released last week.

    Earlier today, UBS analyst Marc Goodman and his team weighed into the fray, proclaiming that a misunderstood situation creates opportunity.

    Goodman, who rates Mallinckrodt at a buy with a $92 price target, argues that Mallinckrodt is a different breed from other specialty drug makers, with high-quality earnings, sales growth fueled by volume not price hikes and an emerging pipeline we think is not just underappreciated but really not even part of the conversation with most investors.

    Also, he argues that Mallinckrodt continues to be misunderstood by investors.

    Goodman goes into goes into more detail:

    we were surprised this past week by the debate around Acthar’s Medicare exposure (~30% or ~40%), which in our view has little relevance to the overall MNK story. The key debate since the Questcor deal has been Acthar payer coverage and concerns for more barriers andor coverage blocks by the payers. There was reason for concern just 2 years ago, in our view, as several important payers increased barriers. But mgt’s aggressive focus on enhancing clinical and health-economics data to help support better coverage seems to be working and has resulted in improved coverage, which we believe is still not well appreciated.

    Mallinckrodt shares continue to climb today, rising 4.8% to a recent $57.20.

  • [By Keith Speights]

    That’s the question investors are trying to answer about how President Trump’s policies might impact healthcare stocks. So far, specific policy proposals put forward by the president appear likely to cause significant problems for certain healthcare stocks. Here’s why three of President Trump’s policies could be downright terrible for Molina Healthcare(NYSE:MOH), Mallinckrodt (NYSE:MNK), and Illumina (NASDAQ:ILMN).

  • [By Ben Levisohn]

    Mallinckrodt (MNK) tumbled to the bottom of the S&P 500 today after Citron Research accused the company of fraud.

    Getty Images

    Mallinckrodt tumbled 12% to $59.60 today, while the S&P 500 declined 0.2% to 2,176.94.

    Leerink’s Jason Gerberry and Etzer Darout explain the allegations:

    Mallinckrodtshares are down -7-8% based on a short report citing CMS dashboard data which call into question Acthar Gel sales derived from government sources (CMS; Medicaid & Medicare). The report appears to overstate Acthar CMS sales as a percent of total product sales, as the methodology utilized by CMS drug spending dashboard for Medicare spend is based on gross sales, not net., although it’s unclear to what extent Acthar CMS sales are overstated.

    The report suggestsMallinckrodt mgmt understated combined Medicaid/Medicare sales on an investor call, saying it was about a little bit higher than a quarter of the business vs. gross sales on CMS dashboard implying sales were 61% of total Acthar net revenue (an apples to oranges comparison). We dont know the exact net sales of Acthar to Medicare/Medicaid, but we believe it is safe to assume Medicaid, after CPI price penalties had high discounts/rebates and assuming an 80% gross-to-net ratio on the Medicare book ($504m gross) suggests Acthar net sales would be closer to 38-45% range vs. the 61% figure cited in the short-report. Why this may matter Acthar Gel is an old product lacking good randomized, controlled data consistent with most products approved in the modern era. The report appears to be an attempt to call into question whether the government should be paying Acthars average $80-100k net price/patient/year by calling to this to the attention of government figures who have been targeting excessive drug pricing issues. This type of issue became a major headache for Mylan (MYL) investors recently with EpiPen.Mallinckrodt is presenting at a compe

Top 10 Blue Chip Stocks To Invest In 2019: Apollo Education Group, Inc.(APOL)

Advisors’ Opinion:

  • [By Peter Graham]

    The Q1 2017 earnings report for small cap for-profit education stock Apollo Education Group Inc (NASDAQ: APOL) is scheduled for after the market closes on Monday (January 9th). Last February, Apollo Education Groupannounced a definitive agreement to be acquired by a consortium of investors including The Vistria Group, LLC, funds affiliated with Apollo Global Management, LLC (NYSE: APO), and Najafi Companies for $9.50 per share in cash for both Class A and B shares. However, the for-profit education sector along with certain aspects of the Apollo deal have been targeted by the Obama administration and it remains to be seen how the Trump administration will treat the sector and the deal.

Top 10 Blue Chip Stocks To Invest In 2019: Bloomin' Brands, Inc.(BLMN)

Advisors’ Opinion:

  • [By CNBC]

    Tony Tribble, Invision/AP
    Forget about Bloomin’ Onions or boneless wings, for many consumers, the choice of where to dine often comes down to a different factor: which restaurant has the best booze.
    “Alcoholic beverages can be a key driver of traffic, differentiation, and loyalty,” said David Decker, president of Consumer Edge Insight. According to the firm, two factors that keep customers coming back are “selection” and “pricing.”
    Consumer Edge Insight recently surveyed restaurant customers to find out which casual-dining spots generated the most loyalty with their alcoholic beverages.
    Taking the top spot for “selection” was Buffalo Wild Wings (BWLD), with 29 percent of those surveyed saying they were “most likely to visit it most often due to its good selection of alcoholic beverages.”
    Applebee’s (DIN) took the second spot, with 24 percent, and Outback Steakhouse (BLMN) and T.G.I. Friday’s tied for third place with 22 percent each.
    Prices also keep customers coming back to Buffalo Wild Wings.

    When asked which casual-dining brand they were “most likely to visit most often due to its good prices of alcoholic beverages,” Buffalo Wild Wings came out on top with 30 percent. Chili’s (EAT) was No. 2 at 23 percent, and Ruby Tuesday (RT) was third with 22 percent.
    Buffalo Wild Wings has always made alcohol a part of its experience, even making it part of its tagline: “Wings.Beer.Sports.”
    The chain is the No. 1 account for more than 50 different beer brands and recently launched Game Changer, a new beer in a partnership with Redhook Brewery. Priced between cheaper domestic lagers and pricier craft beers, Game Changer became the fourth-most-popular draft beer at company-owned locations within two weeks of its release.
    “Among casual-dining restaurants, Buffalo Wild Wings is seeing the greatest positive effect in terms of building customer loyalty with its alcohol offerings,” Decker said. “There are many steps other restaurants can take to improve their alcoho

Top 10 Blue Chip Stocks To Invest In 2019: Cellect Biotechnology Ltd. (APOP)

Advisors’ Opinion:

  • [By Chris Lange]

    Cellect Biotechnology Ltd. (NASDAQ: APOP) reported that it received a formal notice from the U.S. Patent and Trademark Office (USPTO)regarding its method of treatment for immune related disorders. Basically, the USPTO gave a notice of allowance which broadly means the agency intends to issue a patent approval. The treatment method relates to the engineering of regulatory immune cells with enhanced apoptotic activity used for the treatment or prevention for the unmet needs seen in type 1 diabetes, inflammatory bowel disease, graft versus host disease, and transplant rejection.

  • [By Lisa Levin]

    Cellect Biotechnology Ltd. – American Depositary Shares (NASDAQ: APOP) shares were also up, gaining 135 percent to $7.79 after the company disclosed that it has received a notice of allowance from the US Patent Office protecting its technology in multiple key indications.

Top 10 Blue Chip Stocks To Invest In 2019: Smith & Wesson Holding Corporation(SWHC)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows Sturm, Ruger & Company underperforming volatile higher flying competitors or peers like small cap gun stock American Outdoor Brands Corp (NASDAQ: AOBC), formerly Smith & Wesson Holding Corp (NASDAQ: SWHC), and electronic control device maker TASER International, Inc (NASDAQ: TASR):

  • [By Peter Graham]

    A long term performance chart shows Sturm, Ruger & Company underperforming more volatile and higher flying competitors or peers like small cap gun stock American Outdoor Brands Corp (NASDAQ: AOBC), formerly Smith & Wesson Holding Corp (NASDAQ: SWHC), and electronic control device maker Axon Enterprise (NASDAQ: AAXN), formerlyTASER International, Inc (NASDAQ: TASR):

  • [By Lisa Levin]

    Shares of Smith & Wesson Holding Corp (NASDAQ: SWHC) were down 12 percent to $21.04. Smith & Wesson reported upbeat results for its second quarter, but issued a weak outlook for its third quarter.

  • [By Peter Graham]

    A long term performance chart shows Sturm, Ruger & Company underperforming more volatile but higher flying competitors or peers like small cap gun stock American Outdoor Brands Corp (NASDAQ: AOBC), formerly Smith & Wesson Holding Corp (NASDAQ: SWHC), and electronic control device maker Axon Enterprise (NASDAQ: AAXN), formerlyTASER International, Inc (NASDAQ: TASR):

  • [By Chris Lange]

    Smith & Wesson Holding Corp. (NASDAQ: SWHC) reported fiscal second-quarter financial results after markets closed on Thursday. The company said that it had $0.68 in earnings per share (EPS) and $233.5 million in revenue, versus consensus estimates from Thomson Reuters called for $0.56 in EPS and $227.61 million in revenue. The same period from last year had $0.25 in EPS and $143.24 million in revenue.

Leave a Reply

Your email address will not be published. Required fields are marked *